As Washington Clamps Down on Big Pharma, Small Is Beautiful Again
Large drug companies need innovation to deal with the drug-pricing law. That is a boon to smaller biotech firms.
Monday, September 7, 2026
Tag: Healthcare/Life Sciences
Even Mark Cuban Can’t Fix This Broken Drug System
Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices.
Icahn Is No Saint, but Illumina Can Still Use a Flawed Savior
Despite a short seller’s accusations that his company has inflated its asset prices, Carl Icahn’s effort to shake up Illumina’s ...
Eli Lilly Results Signal Arrival of Blockbuster New Drug Class
ShareListen(2 min)
WSJ News Exclusive | J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market
Kenvue plans to start meeting with prospective investors as early as Monday.
The Return-to-Normal Healthcare Trade Picks Up Pace
Healthcare is finally getting back to normal, which is good news for medical-device makers and hospitals, but not for insurers.
WeightWatchers Gets a Makeover With Obesity-Drug Business
MarketsHeard on the StreetThe decision to get into the business for drugs such as Ozempic makes sense
WSJ News Exclusive | Merck in Late-Stage Talks to Acquire Prometheus Biosciences
Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a ...
WSJ News Exclusive | Farallon Capital to Wage Proxy Battle at Biotech Firm
WSJ News ExclusiveFinanceFarallon has nominated three directors to the board of Exelixis
Regeneron and Sanofi Look for Billions From COPD Drug
The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
EDITOR'S PICK
EP NEWSROOM
© 2025 Edinburg Post or its affiliated companies.